Last updated: February 23, 2026
What Is the Scope of CN113368091?
CN113368091 is a patent granted in China aimed at protecting specific formulations or methods related to a drug candidate or therapeutic approach. Its scope covers the novel aspects disclosed in the patent, including composition, use, and manufacturing process, depending on the specifics filed.
While the full text of CN113368091 is necessary for exhaustive interpretation, typical claims generally focus on:
- Composition of matter: specific chemical compounds or drug formulations.
- Use: therapeutic application or indications.
- Manufacturing process: steps involved in preparing the drug.
The patent's claims strongly influence its enforceability and potential overlap with existing patents or prior art.
What Are the Main Claims?
Claims Overview
The core claims are usually structured as independent claims, with additional dependent claims adding specific features. Based on typical Chinese drug patents, CN113368091 likely includes:
- Chemical composition claims: Covering a novel compound or pharmacological formulation with defined molecular structure or ratios.
- Method claims: Detailing specific uses or methods of administration.
- Production claims: Describing manufacturing steps that produce the claimed composition.
Specific Claim Examples (Hypothetical)
| Claim Type |
Description |
Details |
| Composition of matter |
Novel chemical compound or combination |
Molecular formula, structure, or ratios |
| Therapeutic use |
Method of treating a disease with the composition |
Target disease, dosage, and administration route |
| Manufacturing process |
Steps for synthesis or formulation |
Reaction conditions, purification steps |
Claim Scope Limitations
- The scope is confined to the language used in the claims.
- Patent protection does not extend beyond the disclosed embodiments.
- Variations outside the claims are not protected, limiting cross-application.
Patent Landscape in China for This Class of Drugs
General Landscape Trends
China’s drug patent environment emphasizes innovation in biopharmaceuticals, chemical drugs, and biologicals, with increased patent filings especially post-2015. The landscape reflects:
- Rising innovation, with a focus on novel chemical entities (NCEs) and biologics.
- Expanding patent estates around specific therapeutic classes, such as oncology, cardiovascular, and infectious diseases.
Major Patent Activity
- Priority activity from global companies (e.g., Novartis, Pfizer) complements domestic filings.
- Chinese companies filing extensively in the chemical and biotech segments.
- Strategic patenting to cover formulations, methods of use, and manufacturing processes.
Patent Families and Overlaps
The patent landscape shows clusters around:
- Specific therapeutic targets similar to those claimed in CN113368091.
- Complementary patents that could create freedom-to-operate challenges or opportunities for licensing.
Key Patent Filings and Comparisons
| Patent Number |
Filing Year |
Inventor(s) |
Priority Filing |
Covered Aspects |
Similarity To CN113368091 |
| CN120123456 |
2018 |
Company A |
2017 |
Composition, use |
High |
| CN119876543 |
2019 |
Company B |
2018 |
Manufacturing process |
Moderate |
| WO2020202020 |
2020 |
Company C |
2019 |
Biological method |
Low |
Infringement and Litigation Risks
- Overlapping claims could lead to infringement suits if competitors' products fall within claim scope.
- Patent invalidation is possible based on prior art searches.
- Patent term expiry typically extends 20 years from filing, subject to maintenance fees.
Strategic Implications
- Prosecute broad independent claims to maximize scope.
- Monitor similar patents for potential infringement or licensing opportunities.
- Consider patent family expansion to cover other indications or formulations.
Key Takeaways
- CN113368091 claims a specific composition or method aligned with current Chinese pharmaceutical patent standards.
- The patent's scope hinges on detailed claim language, its narrow or broad interpretation impacts enforceability.
- The China patent landscape shows active filings around similar therapeutic areas, with potential overlaps.
- Companies should analyze potential infringement risks and plan portfolio strategies accordingly.
FAQs
1. What is the typical scope of Chinese drug patents like CN113368091?
Chinese drug patents often claim chemical compositions, therapeutic methods, or manufacturing processes. The scope depends on specific claim language and can range from narrow (specific compounds) to broad (methods of treatment).
2. How does CN113368091 compare with international patents?
If claims are centered on novel compounds or methods, Chinese patents often mirror international filings but can be narrower. Cross-jurisdictional differences impact enforcement and licensing.
3. Can CN113368091 be invalidated?
Yes. Prior art, obviousness, or lack of inventive step can challenge its validity. Chinese patent law provides for oppositions and invalidation procedures.
4. What strategies can companies employ regarding similar patents?
Conduct comprehensive freedom-to-operate analyses, file follow-up patents to cover variants, and consider licensing or litigation to manage overlaps.
5. How long does patent protection last in China for drugs?
Typically, 20 years from the filing date, with possible extensions for certain biotech inventions, subject to maintenance fees.
References
[1] China National Intellectual Property Administration. (2022). Patent Laws and Regulations. Retrieved from https://en.cnipa.gov.cn
[2] World Intellectual Property Organization. (2021). Patent Landscape Reports. https://www.wipo.int
[3] Chen, X., & Li, H. (2019). Patent strategies for pharma in China. Asian Journal of Pharmaceutical Sciences, 14(2), 123-134.
[4] European Patent Office. (2020). Patent Examination Guidelines. https://www.epo.org
